Top 10 HIV Clinical Developments of 2019Providing Quality HIV CareTop 10 HIV Clinical Developments of 2019David Alain Wohl, M.D.9 Min ReadWill a given development in HIV make a difference in the clinic? Will it change practice? Is this something I should know if I take care of people living with HIV? The answer to each of these must be yes for the story to make the list. Adverse Events & ComorbiditiesWeight Gain and HIV Antiretrovirals: Lipodystrophy for the Integrase EraDavid Alain Wohl, M.D.6 Min ReadIn a busy year buzzing with the flight of potentially revolutionary new HIV medications, evidence of large weight increases accompanying dolutegravir and bictegravir has been a bombshell. Adverse Events & ComorbiditiesWeight Gain and HIV Antiretrovirals: Lipodystrophy for the Integrase EraDavid Alain Wohl, M.D.6 Min ReadIn a busy year buzzing with the flight of potentially revolutionary new HIV medications, evidence of large weight increases accompanying dolutegravir and bictegravir has been a bombshell. Antiretroviral TherapyTANGO, the Most Relevant Two-Drug Antiretroviral Therapy Trial of the YearDavid Alain Wohl, M.D.4 Min ReadWhether lamivudine/dolutegravir is sufficient to achieve and maintain viral suppression was last year's question. As we move to 2020, a new question could be asked: Are three-drug regimens still necessary? Antiretroviral TherapyTANGO, the Most Relevant Two-Drug Antiretroviral Therapy Trial of the YearDavid Alain Wohl, M.D.4 Min ReadWhether lamivudine/dolutegravir is sufficient to achieve and maintain viral suppression was last year's question. As we move to 2020, a new question could be asked: Are three-drug regimens still necessary? PrEP (HIV Pre-Exposure Prophylaxis)And Then There Were Two: FTC/TAF Is Also PrEPDavid Alain Wohl, M.D.5 Min ReadGiven similar efficacy and the renal and bone benefits, TAF/FTC should be favored over TDF/FTC. But as David Wohl, M.D., explains, the reality isn't so simple. PrEP (HIV Pre-Exposure Prophylaxis)And Then There Were Two: FTC/TAF Is Also PrEPDavid Alain Wohl, M.D.5 Min ReadGiven similar efficacy and the renal and bone benefits, TAF/FTC should be favored over TDF/FTC. But as David Wohl, M.D., explains, the reality isn't so simple. Perinatal Care & PregnancyTsepamo Study Provides Critical Update on Neural Tube Defects and DolutegravirDavid Alain Wohl, M.D.3 Min ReadA lot of pregnancies in Botswana were anxiously followed after results from the Tsepamo study were revealed in late 2018. Updated data provide a medium-sized sigh of relief. Perinatal Care & PregnancyTsepamo Study Provides Critical Update on Neural Tube Defects and DolutegravirDavid Alain Wohl, M.D.3 Min ReadA lot of pregnancies in Botswana were anxiously followed after results from the Tsepamo study were revealed in late 2018. Updated data provide a medium-sized sigh of relief. HIV Treatments in DevelopmentATLAS, FLAIR, and the Upcoming Arrival of Long-Acting Injectable HIV TreatmentDavid Alain Wohl, M.D.4 Min ReadThe likely launch of injectable cabotegravir/rilpivirine in early 2020 will be interesting, writes David Wohl, M.D. One big question: How smoothly will the rollout go? HIV Treatments in DevelopmentATLAS, FLAIR, and the Upcoming Arrival of Long-Acting Injectable HIV TreatmentDavid Alain Wohl, M.D.4 Min ReadThe likely launch of injectable cabotegravir/rilpivirine in early 2020 will be interesting, writes David Wohl, M.D. One big question: How smoothly will the rollout go? HIV Treatments in DevelopmentIslatravir Is Potent and Long-Lasting -- and May Be Having an Identity CrisisDavid Alain Wohl, M.D.3 Min ReadThis is clearly an antiretroviral not built for daily administration. But then what is it destined for? HIV Treatments in DevelopmentIslatravir Is Potent and Long-Lasting -- and May Be Having an Identity CrisisDavid Alain Wohl, M.D.3 Min ReadThis is clearly an antiretroviral not built for daily administration. But then what is it destined for? Managing HIV Drug ResistanceDAWNING Study Casts New Light on the Details of ResistanceDavid Alain Wohl, M.D.5 Min ReadThe findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen. Managing HIV Drug ResistanceDAWNING Study Casts New Light on the Details of ResistanceDavid Alain Wohl, M.D.5 Min ReadThe findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen. HIV and Mental HealthThe Tangled Knot of Suicide Rates Among People Living With HIVDavid Alain Wohl, M.D.2 Min ReadSobering data make clear that in HIV clinics, depression screening is as important as STI screening. HIV and Mental HealthThe Tangled Knot of Suicide Rates Among People Living With HIVDavid Alain Wohl, M.D.2 Min ReadSobering data make clear that in HIV clinics, depression screening is as important as STI screening. Policy & AdvocacyThe Ironies of a New Plan to End the U.S. HIV EpidemicDavid Alain Wohl, M.D.4 Min ReadThe attention of this specific U.S. president on HIV is curious. However, while it may be initially disorienting, it makes sense, explains David Wohl, M.D. Policy & AdvocacyThe Ironies of a New Plan to End the U.S. HIV EpidemicDavid Alain Wohl, M.D.4 Min ReadThe attention of this specific U.S. president on HIV is curious. However, while it may be initially disorienting, it makes sense, explains David Wohl, M.D. Policy & AdvocacyA Final Tribute to Charles van der HorstDavid Alain Wohl, M.D.3 Min ReadAlthough you may not have known -- or even heard of -- Charles van der Horst, his DNA is woven into the cloth of HIV care and research. Policy & AdvocacyA Final Tribute to Charles van der HorstDavid Alain Wohl, M.D.3 Min ReadAlthough you may not have known -- or even heard of -- Charles van der Horst, his DNA is woven into the cloth of HIV care and research.
